TMCnet

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

For further information on the two studies, please see Biofrontera’s press releases 3,4 from September 16, 2025, and August 25, 2025. The 1-year follow-up phase of the phase III study on AK is still ...
National Institute for Health and Care Excellence

Ambulight PDT for the treatment of non-melanoma skin cancer

The committee considered that there was some evidence for efficacy of Ambulight PDT but that the quantity of evidence on its use was very limited. The committee considered that more clinical evidence ...
Seeking Alpha

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of PDT, ...
Nasdaq

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic ...

WOBURN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
National Institute for Health and Care Excellence

Ambulight PDT for the treatment of non-melanoma skin cancer

The purpose of the Ambulight PDT device (Ambicare Health Ltd) is to deliver PDT to treat non-melanoma skin cancer in an ambulatory setting, including patients' homes in selected cases. Ambulight PDT ...